| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Janet A Schlecht. Update in pituitary 2010. The Journal of clinical endocrinology and metabolism. vol 96. issue 1. 2011-02-04. PMID:21209039. |
issues addressed include the safety of cabergoline in pregnancy, recurrence of hyperprolactinemia after dopamine agonist withdrawal, pegvisomant and hepatic dysfunction, and high-dose hydrocortisone as a predictor of mortality in patients with acromegaly. |
2011-02-04 |
2023-08-12 |
Not clear |
| O M Dekkers, J A Romijn, A de Boer, J P Vandenbrouck. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary. vol 13. issue 3. 2010-11-16. PMID:20012697. |
of these, 1,607 subjects were considered to have dopamine agonist-treated hyperprolactinemia based on the prescribing pattern. |
2010-11-16 |
2023-08-12 |
human |
| Ryosuke Arakawa, Masaki Okumura, Hiroshi Ito, Akihiro Takano, Hidehiko Takahashi, Harumasa Takano, Jun Maeda, Yoshiro Okubo, Tetsuya Suhar. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. The Journal of clinical psychiatry. vol 71. issue 9. 2010-10-22. PMID:20361897. |
positron emission tomography measurement of dopamine d₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. |
2010-10-22 |
2023-08-12 |
Not clear |
| Christos C Zouboulis, Thomas Rab. [Hormonal antiandrogens in acne treatment]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. vol 8 Suppl 1. 2010-10-14. PMID:20482693. |
concerning their mechanism of action, hormonal antiandrogens are classified in androgen receptor blockers, inhibitors of circulating androgens by affecting the ovarial function (oral contraceptives), inhibitors of circulating androgens by affecting the pituitary (gonadotrophin-releasing hormone agonists and dopamin agonists in hyperprolactinemia), inhibitors of the adrenal function, and inhibitors of peripheral androgen metabolism (5-reductase inhibitors, inhibitors of other enzymes). |
2010-10-14 |
2023-08-12 |
Not clear |
| Juan Rivera, Synnove Alves, Caterina Chiara Bianchi, Nawal Al-Mutawa, Marie Christine Guiot, Anthony Zeitoun. An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region. Pituitary. vol 13. issue 2. 2010-08-17. PMID:18846427. |
we suggest that in the presence of extensive cranial nerve involvement, atypical imaging findings for a pituitary adenoma and severe hyperprolactinemia, the possibility of a collision tumor should lead the physician to consider excisional tumor biopsy or surgery in addition to dopamine agonist therapy. |
2010-08-17 |
2023-08-12 |
Not clear |
| Sophie Bernichtein, Philippe Touraine, Vincent Goffi. New concepts in prolactin biology. The Journal of endocrinology. vol 206. issue 1. 2010-07-01. PMID:20371569. |
serum levels) is controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia. |
2010-07-01 |
2023-08-12 |
human |
| Norio Yasui-Furukori, Manabu Saito, Taku Nakagami, Norio Sugawara, Yasushi Sato, Shoko Tsuchimine, Hanako Furukori, Sunao Kanek. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 3. 2010-06-24. PMID:20170699. |
hyperprolactinemia is a frequent consequence of treatment with antipsychotic agents, partially because the prolactin response to antipsychotics is related to dopamine blockade. |
2010-06-24 |
2023-08-12 |
human |
| Mark E Molitc. Pituitary gland: can prolactinomas be cured medically? Nature reviews. Endocrinology. vol 6. issue 4. 2010-06-18. PMID:20336161. |
has assessed the effects of dopamine agonist withdrawal in patients with hyperprolactinemia. |
2010-06-18 |
2023-08-12 |
Not clear |
| M Lafeber, A M E Stades, G D Valk, M J Cramer, F Teding van Berkhout, P M J Zelisse. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. European journal of endocrinology. vol 162. issue 4. 2010-04-27. PMID:20071478. |
cabergoline, a dopamine agonist used to treat hyperprolactinemia, is associated with an increased risk of fibrotic adverse reactions, e.g. |
2010-04-27 |
2023-08-12 |
Not clear |
| Elena Valassi, Anne Klibanski, Beverly M K Bille. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 95. issue 3. 2010-03-31. PMID:20130078. |
clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. |
2010-03-31 |
2023-08-12 |
Not clear |
| Sophie Vallette, Karim Serri, Omar Serr. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert review of cardiovascular therapy. vol 8. issue 1. 2010-03-17. PMID:20014934. |
dopamine agonists (das) are the first-line therapy for the treatment of hyperprolactinemia, with cabergoline, an ergot-derived selective d(2)-receptor agonist, being the preferred and most widely used drug. |
2010-03-17 |
2023-08-12 |
Not clear |
| Olaf M Dekkers, Joep Lagro, Pia Burman, Jens Otto Jørgensen, Johannes A Romijn, Alberto M Pereir. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. vol 95. issue 1. 2010-02-01. PMID:19880787. |
recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. |
2010-02-01 |
2023-08-12 |
Not clear |
| Olaf M Dekkers, Joep Lagro, Pia Burman, Jens Otto Jørgensen, Johannes A Romijn, Alberto M Pereir. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. vol 95. issue 1. 2010-02-01. PMID:19880787. |
dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. |
2010-02-01 |
2023-08-12 |
Not clear |
| M Kars, P C Souverein, R M C Herings, J A Romijn, J P Vandenbroucke, A de Boer, O M Dekker. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 94. issue 8. 2009-08-25. PMID:19491225. |
estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. |
2009-08-25 |
2023-08-12 |
Not clear |
| Ken H Darzy, Stephen M Shale. Hypopituitarism following radiotherapy. Pituitary. vol 12. issue 1. 2009-08-21. PMID:18270844. |
hyperprolactinemia, due to hypothalamic damage leading to reduced dopamine release, has been described in both sexes and all ages but is mostly seen in young women after intensive irradiation and is usually subclinical. |
2009-08-21 |
2023-08-12 |
Not clear |
| Chadi A Calarge, Vicki L Ellingrod, Laura Acion, Del D Miller, Jessica Moline, Michael J Tansey, Janet A Schlecht. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. vol 19. issue 5. 2009-06-17. PMID:19339912. |
variants of the dopamine d2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. |
2009-06-17 |
2023-08-12 |
Not clear |
| Chadi A Calarge, Vicki L Ellingrod, Laura Acion, Del D Miller, Jessica Moline, Michael J Tansey, Janet A Schlecht. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. vol 19. issue 5. 2009-06-17. PMID:19339912. |
to investigate the association between hyperprolactinemia and variants of the dopamine d2 receptor (drd2) gene in children and adolescents in long-term treatment with risperidone. |
2009-06-17 |
2023-08-12 |
Not clear |
| Donal C Skinne. Rethinking the stalk effect: a new hypothesis explaining suprasellar tumor-induced hyperprolactinemia. Medical hypotheses. vol 72. issue 3. 2009-04-28. PMID:19028420. |
it has been postulated that these suprasellar tumors induce hyperprolactinemia by compressing the pituitary stalk, resulting in impaired dopamine delivery to the pituitary and, consequently, disinhibition of the lactotropes. |
2009-04-28 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Manabu Saito, Shoko Tsuchimine, Taku Nakagami, Yasushi Sato, Norio Sugawara, Sunao Kanek. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 6. 2008-10-22. PMID:18579277. |
hyperprolactinemia is an inevitable consequence of treatment with antipsychotic agents to some extent because prolactin response to antipsychotics is related to dopamine blockade. |
2008-10-22 |
2023-08-12 |
human |
| Mark E Molitc. Drugs and prolactin. Pituitary. vol 11. issue 2. 2008-09-19. PMID:18404390. |
if the hyperprolactinemia is symptomatic, management strategies include switching to an alternative medication which does not cause hyperprolactinemia, using estrogen/testosterone replacement, or cautiously adding a dopamine agonist. |
2008-09-19 |
2023-08-12 |
Not clear |